Research paperParicalcitol accelerates BACE1 lysosomal degradation and inhibits calpain-1 dependent neuronal loss in APP/PS1 transgenic mice

Add time:08/31/2019    Source:sciencedirect.com

BackgroundRecent studies have revealed that vitamin D deficiency may increase the risk of Alzheimer's disease, and vitamin D supplementation may be effective strategy to ameliorate the neurodegenerative process in Alzheimer's disease patients. Paricalcitol (PAL), a low-calcemic vitamin D receptor agonist, is clinically used to treat secondary hyperparathyroidism. However, the potential application of PAL for treating neurodegenerative disorders remains unexplored.

We also recommend Trading Suppliers and Manufacturers of pal-1 protein (cas 138391-18-1). Pls Click Website Link as below: cas 138391-18-1 suppliers

Prev:Synthesis of an electronically-tuned minimally interfering alkynyl photo-affinity label to measure small molecule–protein interactions
Next:The ELAV family of RNA-binding proteins in synaptic plasticity and long-term memory)